{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:05:09Z","timestamp":1778875509952,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["No. 20201BBG71008"],"award-info":[{"award-number":["No. 20201BBG71008"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["No. 20201BBG71008"],"award-info":[{"award-number":["No. 20201BBG71008"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00384-022-04214-7","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T18:04:40Z","timestamp":1656785080000},"page":"1525-1534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Xuehui","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaisaner","family":"Rexiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6479-0369","authenticated-orcid":false,"given":"Xiaohua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"issue":"1","key":"4214_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","volume":"7","author":"JY Blay","year":"2021","unstructured":"Blay JY, Kang YK, Nishida T, von Mehren M (2021) Gastrointestinal stromal tumours. Nat Rev Dis Primers 7(1):22. https:\/\/doi.org\/10.1038\/s41572-021-00254-5","journal-title":"Nat Rev Dis Primers"},{"issue":"5350","key":"4214_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (New York, NY) 279(5350):577\u2013580. https:\/\/doi.org\/10.1126\/science.279.5350.577","journal-title":"Science (New York, NY)"},{"issue":"5607","key":"4214_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science (New York, NY) 299(5607):708\u2013710. https:\/\/doi.org\/10.1126\/science.1079666","journal-title":"Science (New York, NY)"},{"issue":"46","key":"4214_CR4","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.3748\/wjg.v24.i46.5189","volume":"24","author":"J Li","year":"2018","unstructured":"Li J, Wang M, Zhang B, Wu X et al (2018) Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World J Gastroenterol 24(46):5189\u20135202. https:\/\/doi.org\/10.3748\/wjg.v24.i46.5189","journal-title":"World J Gastroenterol"},{"key":"4214_CR5","doi-asserted-by":"publisher","unstructured":"Nishida T, Doi T, Naito Y (2014) Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert Opin Pharmacother 15(14):1979\u20131989. https:\/\/doi.org\/10.1517\/14656566.2014.937707","DOI":"10.1517\/14656566.2014.937707"},{"issue":"3","key":"4214_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ejso.2018.08.001","volume":"45","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhou Y, Wu X, Nie M, Zhang B, Zhou Y, Sun L, Liu Z, Liu X, Kou Y, Wang Y, Zhang Y, Hao C, Shen L, Li J (2019) Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study. Eur J Surg Oncol 45(3):318\u2013323. https:\/\/doi.org\/10.1016\/j.ejso.2018.08.001","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"4214_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11864-022-00958-0","volume":"23","author":"J Senchak","year":"2022","unstructured":"Senchak J, Ahr K, von Mehren M (2022) Gastrointestinal stromal tumors: what is the best sequence of TKIs? Curr Treat Options Oncol 23(5):749\u2013761. https:\/\/doi.org\/10.1007\/s11864-022-00958-0","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"4214_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","volume":"16","author":"X Le","year":"2021","unstructured":"Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, Ares LP, Frimodt-Moller B, Wolff K, Visseren-Grul C, Heymach JV, Garon EB (2021) Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol 16(2):205\u2013215. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.006","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4214_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali PG, Blay JY, Abecassis N et al (2022) Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 33(1):20\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.005","journal-title":"Ann Oncol"},{"issue":"33","key":"4214_CR10","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/jco.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clinic Oncol\u202f: Official J Am Soc Clinic Oncol 26(33):5352\u20135359. https:\/\/doi.org\/10.1200\/jco.2007.15.7461","journal-title":"J Clinic Oncol : Official J Am Soc Clinic Oncol"},{"issue":"9669","key":"4214_CR11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/s0140-6736(09)60500-6","volume":"373","author":"RP Dematteo","year":"2009","unstructured":"Dematteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 373(9669):1097\u20131104. https:\/\/doi.org\/10.1016\/s0140-6736(09)60500-6","journal-title":"Lancet (London, England)"},{"key":"4214_CR12","doi-asserted-by":"publisher","unstructured":"van de Wal D, Elie M, Le Cesne A, Fumagalli E, den Hollander D, Jones RL, Marquina G, Steeghs N, van der Graaf WTA, Husson O (2022) Health-related quality of life and side effects in gastrointestinal stromal tumor (GIST) patients treated with tyrosine kinase inhibitors: a systematic review of the literature. Cancers (Basel) 14(7). https:\/\/doi.org\/10.3390\/cancers14071832","DOI":"10.3390\/cancers14071832"},{"issue":"6","key":"4214_CR13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s10147-012-0497-2","volume":"18","author":"EM Ibrahim","year":"2013","unstructured":"Ibrahim EM, Kazkaz GA, Abouelkhair KM, Bayer AM, Elmasri OA (2013) Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol 18(6):1060\u20131069. https:\/\/doi.org\/10.1007\/s10147-012-0497-2","journal-title":"Int J Clin Oncol"},{"key":"4214_CR14","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj 339(1):b2535\u2013b2535. https:\/\/doi.org\/10.1136\/bmj.b2535","DOI":"10.1136\/bmj.b2535"},{"issue":"11","key":"4214_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","volume":"45","author":"S George","year":"2009","unstructured":"George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45(11):1959\u20131968. https:\/\/doi.org\/10.1016\/j.ejca.2009.02.011","journal-title":"Eur J Cancer"},{"issue":"9","key":"4214_CR16","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/cncr.29220","volume":"121","author":"P Reichardt","year":"2015","unstructured":"Reichardt P, Kang YK, Rutkowski P et al (2015) Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer 121(9):1405\u20131413. https:\/\/doi.org\/10.1002\/cncr.29220","journal-title":"Cancer"},{"issue":"9544","key":"4214_CR17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/s0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. The Lancet 368(9544):1329\u20131338. https:\/\/doi.org\/10.1016\/s0140-6736(06)69446-4","journal-title":"The Lancet"},{"issue":"9","key":"4214_CR18","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/annonc\/mdu237","volume":"25","author":"A Adenis","year":"2014","unstructured":"Adenis A, Blay JY, Bui-Nguyen B et al (2014) Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann Oncol 25(9):1762\u20131769. https:\/\/doi.org\/10.1093\/annonc\/mdu237","journal-title":"Ann Oncol"},{"issue":"18","key":"4214_CR19","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1158\/1078-0432.CCR-09-0482","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Heinrich MC, Fletcher JA et al (2009) Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 15(18):5902\u20135909. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0482","journal-title":"Clin Cancer Res"},{"key":"4214_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1471-2407-12-107","volume":"12","author":"P Rutkowski","year":"2012","unstructured":"Rutkowski P, Bylina E, Klimczak A et al (2012) The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer 12:107. https:\/\/doi.org\/10.1186\/1471-2407-12-107","journal-title":"BMC Cancer"},{"key":"4214_CR21","doi-asserted-by":"publisher","unstructured":"Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A (2010) Phase I\/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 28(6):866\u2013875. https:\/\/doi.org\/10.1007\/s10637-009-9306-9","DOI":"10.1007\/s10637-009-9306-9"},{"issue":"7","key":"4214_CR22","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/annonc\/mdr598","volume":"23","author":"P Reichardt","year":"2012","unstructured":"Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y, Galetic I, Rutkowski P (2012) Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 23(7):1680\u20131687. https:\/\/doi.org\/10.1093\/annonc\/mdr598","journal-title":"Ann Oncol"},{"issue":"2","key":"4214_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40487-017-0052-4","volume":"5","author":"L Shen","year":"2017","unstructured":"Shen L, Sun Y, Xu J-M, Linn C, Wang Q, Yang L-Q, Qin S-K (2017) Phase IV Study of sunitinib in Chinese patients with imatinib-resistant or imatinib-intolerant gastrointestinal stromal tumors. Oncology and Therapy 5(2):171\u2013180. https:\/\/doi.org\/10.1007\/s40487-017-0052-4","journal-title":"Oncology and Therapy"},{"key":"4214_CR24","doi-asserted-by":"publisher","unstructured":"Sahu A, Godbole S, Jain P, Ghosh J, Shrikhande S, Ramadwar M, Goyal M, Gulia S, Bajpai J, Kembhavi Y, Gupta S (2015) Sunitinib in patients with imatinib-resistant gastrointestinal stromal tumor: a single center experiencep-190 chronic myelogenous leukemia presenting as extramedullary blast crisis. Indian J Cancer 52(3). https:\/\/doi.org\/10.4103\/0019-509x.176747","DOI":"10.4103\/0019-509x.176747"},{"issue":"5","key":"4214_CR25","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jgo.2018.03.009","volume":"9","author":"P Rutkowski","year":"2018","unstructured":"Rutkowski P, Bylina E, Lugowska I, Teterycz P, Klimczak A, Streb J, Czarnecka AM, Osuch C (2018) Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST). J Geriatr Oncol 9(5):520\u2013525. https:\/\/doi.org\/10.1016\/j.jgo.2018.03.009","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"4214_CR26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712\u2013716. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"issue":"5","key":"4214_CR27","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.Ccr-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13(5):1367\u20131373. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-2328","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4214_CR28","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-11-3005","volume":"18","author":"GD Demetri","year":"2012","unstructured":"Demetri GD, Garrett CR, Schoffski P et al (2012) Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 18(11):3170\u20133179. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4214_CR29","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ctrv.2013.01.004","volume":"39","author":"T Funakoshi","year":"2013","unstructured":"Funakoshi T, Latif A, Galsky MD (2013) Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis. Cancer Treat Rev 39(7):818\u2013830. https:\/\/doi.org\/10.1016\/j.ctrv.2013.01.004","journal-title":"Cancer Treat Rev"},{"issue":"6892","key":"4214_CR30","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nature00821","volume":"417","author":"HP Gerber","year":"2002","unstructured":"Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N (2002) VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417(6892):954\u2013958. https:\/\/doi.org\/10.1038\/nature00821","journal-title":"Nature"},{"issue":"1","key":"4214_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/jco.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand J-P, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25\u201335. https:\/\/doi.org\/10.1200\/jco.2005.02.2194","journal-title":"J Clin Oncol"},{"issue":"4","key":"4214_CR32","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood.V91.4.1101","volume":"91","author":"SD Lyman","year":"1998","unstructured":"Lyman SD, Jacobsen SE (1998) c-kit ligand and Flt3 ligand: stem\/progenitor cell factors with overlapping yet distinct activities. Blood 91(4):1101\u20131134","journal-title":"Blood"},{"issue":"7","key":"4214_CR33","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/j.1600-6143.2012.04019.x","volume":"12","author":"Z Aydin","year":"2012","unstructured":"Aydin Z, Mallat MJK, Schaapherder AFM, van Zonneveld AJ, van Kooten C, Rabelink TJ, de Fijter JW (2012) Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant 12(7):1793\u20131800. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04019.x","journal-title":"Am J Transplant"},{"issue":"7","key":"4214_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472\u2013480. https:\/\/doi.org\/10.1056\/NEJMoa020461","journal-title":"N Engl J Med"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-022-04214-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-022-04214-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-022-04214-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T10:22:37Z","timestamp":1657189357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-022-04214-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["4214"],"URL":"https:\/\/doi.org\/10.1007\/s00384-022-04214-7","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"27 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a review article that does not contain human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Formal consent is not required for this type of article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Permission has been obtained from all named authors to submit the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}